[Home]   [Full version]  

Natural protein stops deadly human brain cancer in mice

Dec 07 ,Medicine & Health


Scientists from Johns Hopkins and from the University of Milan have effectively proven that they can inhibit lethal human brain cancers in mice using a protein that selectively induces positive changes in the activity of cells that behave like cancer stem cells. The report is published this week in Nature.

The most common type of brain cancer-glioblastoma-is marked by the presence of these stem-cell-like brain cells, which, instead of triggering the replacement of damaged cells, form cancer tissue. Stem cells, unlike all other cells in the body, are capable of forming almost any kind of cell when the right "signals" trigger their development.

For their treatment experiment, the researchers relied on a class of proteins, bone morphogenic proteins, that cause neural stem-cell-like clusters to lose their stem cell properties, which in turn stops their ability to divide.

First they pretreated human glioblastoma cells with bone morphogenic protein 4 (BMP4), then injected these treated cells into mouse brains. In mice injected with cells that were not pretreated, large, invasive cancers grew. In the mice with BMP4-treated cells, no cancers grew at all. Three to four months after injection, all mice that got untreated cells died, and nearly all mice with BMP4-treated cells were alive.

Next, the scientists delivered slow-release BMP4-containing "beads" directly into mouse brains with implanted glioblastoma cells. Mice that got empty beads developed large malignant tumors and died. Mice with BMP4 beads survived much longer, and 80 percent survived four months after cancer cell implants.

"Our idea is to treat patients with BMP4 or something like it right after surgery to remove glioblastoma in hopes of preventing the regrowth of the cancer and improving survival time," says Alessandro Olivi, M.D., director of the Division of Neurosurgical Oncology at Hopkins and a contributor to the study.

Olivi says clinical studies using BMP4 could begin within a year and, if successful, drug therapies could be available to the public within three to four years.

"This was proof of the idea that BMPs could stop glioblastoma by depleting the stem-cell-like population that feeds it," says Henry Brem, M.D., chairman of the Department of Neurosurgery at Hopkins and a collaborator in the study. "This opens exciting doors to future research into treatments and therapies for such a devastating disease."

Source: Johns Hopkins Medical Institutions

Related stories:

Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.
Scientists identify a molecule that coordinates the movement of cells
Even cells commute. To get from their birthplace to their work site, they sequentially attach to and detach from an elaborate track of exceptionally strong proteins known as the extracellular matrix. Now, in research to appear in the October 3 issue of Cell, scientists at the Howard Hughes Medical Institute and Rockefeller University show that a molecule, called ACF7, helps regulate and power this movement from the inside - findings that could have implications for understanding how cancer cells metastasize.
Researchers develop novel anti-tumor vaccine
A novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice, according to new research published in the October edition of the research journal Cancer Immunology, Immunotherapy. The vaccine uses the tumor's own protein to induce an immune system response, allowing for a personalized approach to treatment.
Vitamin C reduces benefits of cancer drugs: study
Vitamin C supplements may significantly reduce the effectiveness of several anti-cancer drugs, according to a new study published Wednesday.
'Hub' of fear memory formation identified in brain cells
A protein required for the earliest steps in embryonic development also plays a key role in solidifying fear memories in the brains of adult animals, scientists have revealed. An apparent "hub" for changes in the connections between brain cells, beta-catenin could be a potential target for drugs to enhance or interfere with memory formation.
New way to control protein activity could lead to cancer therapies
Investigators at the Stanford University School of Medicine have found a way to quickly and reversibly fine-tune the activity of individual proteins in cells and living mammals, providing a powerful new laboratory tool for identifying — more precisely than ever before — the functions of different proteins.
Hybrid Nanoparticles Image and Treat Tumors
(PhysOrg.com) -- By combining a magnetic nanoparticle, a fluorescent quantum dot, and an anticancer drug within a lipid-based nanoparticle, a multi-institutional research team headed by members of the National Cancer Institute’s (NCI) Alliance for Nanotechnology in Cancer has created a single agent that can image and treat tumors. In addition, this new nanoparticle is able to avoid detection by the immune system, enabling the particle to remain in the body for extended periods of time.
Important new step toward producing stem cells for human treatment
(PhysOrg.com) -- A team of Harvard Stem Cell Institute (HSCI) scientists has taken an important step toward producing induced pluripotent stem (iPS) cells that are safe to transplant into patients to treat diseases.

News discussion:

Natural Protein Stops Deadly - in Medicine & Health news

[Home]   [Full version]